BioLineRx reports excellent results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia BioLineRx , a biopharmaceutical advancement organization, announced today that BL-8040 has been proven in pre-medical trials to work for the treating thrombocytopenia, or decreased platelet creation doctor recommendation caverta.biz . The findings were released in the British Journal of Hematology, a respected journal in the field. The scholarly study, headed by Prof. Amnon Peled from the Goldyne Savad Institute of Gene Therapy – Hadassah University Medical center, assessed the result of repeated doses of BL-8040 upon chemotherapy-induced and healthful thrombocytopenic mice. The results display that repeated administration of BL-8040 considerably increased the amount of megakaryocytes within the bone marrow; this is associated with increased creation and increased degrees of platelets in the bloodstream circulation, in both healthful and chemotherapy induced-thrombocytopenic mice.
what does caverta do
G&A expenses risen to $14.december 31 2 million for the season ended, 2010 from $11.december 31 5 million for the year ended, 2009 primarily because of raises in consulting fees linked to supply chain and other commercial actions, along with legal fees, operating and staff related costs. The web loss for the entire year ended December 31, 2010 was $32.7 million, or $0.73 per talk about, in comparison to a net lack of $13.5 million, or $0.december 31 35 per share for the year ended, 2009. As of 31 December, 2010, the business held cash, money equivalents and securities of $66.3 million, a loss of $28.december 31 0 million as compared to, 2009, and a loss of $5.september 30 7 million compared to, 2010.